Akari Therapeutics files PCT patent application for PH1 RNA-splicing ADC payload in cancer
AKTX•Akari Therapeutics filed a PCT patent application covering its PH1 ADC payload, designed to disrupt RNA splicing in cancers. The filing seeks claims on PH1’s ability to modulate alternative splicing across multiple tumor-driving pathways.
1. Patent application
Akari Therapeutics filed a PCT patent application covering its PH1 ADC payload, which is designed to disrupt RNA splicing in cancers. The filing targets claims on PH1’s ability to modulate alternative splicing across multiple tumor-driving pathways beyond its cytotoxic mechanism.
2. Platform expansion
The portfolio expansion supports Akari’s PH1-based ADC platform, which the brief positions as a differentiated approach versus tubulin inhibitors or DNA-damaging payloads.
